Regeneron Pharmaceuticals Reports Sustained Efficacy of Pasatru in FOP Patients and Announces Weight‑Loss Study Results

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) confirmed that its FDA‑approved therapy, Pasatru (garetosmab‑grts), continues to demonstrate clinically meaningful benefits in adults with fibrodysplasia ossificans progressiva (FOP). The company released data from the 56‑week extension of the OPTIMA trial, showing a 0 % incidence of new heterotopic ossification (HO) lesions and a reduction in clinician‑assessed flare‑ups through week 84. Safety data remained consistent with the core trial, supporting long‑term disease control.

Key Findings from the OPTIMA Extension

  • Zero new HO lesions were observed during the 56‑week extension, maintaining the treatment’s effectiveness established in the core study.
  • Clinician‑assessed flare‑ups were reduced relative to baseline, indicating sustained suppression of disease activity.
  • Safety profile remained stable, with no new adverse events emerging between weeks 56 and 84.

These results were presented on 12 October 2026 and reaffirmed Pasatru’s position as the only FDA‑approved therapy that effectively limits both new HO lesions and flare‑ups in FOP patients.

Additional Company Milestones

Weight‑Loss Study on Lean Mass Preservation

On 14 October 2026, Regeneron announced the outcomes of a study investigating a novel agent’s ability to prevent lean mass and muscle loss during GLP‑1‑mediated weight loss. The data suggest that the compound helps maintain muscle mass in patients undergoing pharmacologic weight reduction, addressing a common limitation of GLP‑1 therapies.

Recognition of Regeneron‑Sponsored Science Fair

Regeneron’s sponsorship of the 76th International Science and Engineering Fair (ISEF) was highlighted on 12 October 2026. The fair, held in Phoenix, Arizona, drew more than 1,700 finalists from 365 affiliated fairs across 60+ countries. Regeneron’s support underscores the company’s commitment to fostering early‑career scientific talent.

Market Context

  • Regeneron’s share price closed at $753.12 on 12 October 2026, within a 52‑week range of $564.00 to $859.34.
  • The company’s market capitalization stands at $77.5 billion, with a price‑earnings ratio of 18.85.
  • NASDAQ activity on 12 October 2026 saw the index decline 0.75 %, reflecting broader market volatility.

Summary

Regeneron’s recent disclosures confirm the sustained clinical efficacy of Pasatru for FOP patients and present promising data on a muscle‑preservation agent for GLP‑1‑based weight loss. The company continues to engage the scientific community through sponsorship of major pre‑college competitions, while maintaining robust market performance amid a fluctuating equity landscape.